Session Information

  • WCLC 2021

    2021 World Conference on Lung Cancer

    Conference Program for 2021 the World Conference on Lung Cancer

    Presentation Date(s):  
    • September 8 - 14, 2021
    • Total Presentations: 1107

    All times listed are in Mountain Time MDT (UTC-6:00)

    PL - Plenary
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    WS - Workshops
    IS - Industry Symposium
    MTE - Meet the Expert
    BEDG - Brain Exchange Discussion Groups

Filter Results:

Show Only CME Accredited Sessions

  • +

    PL02 - Plenary 2: Presidential Symposium (Japanese, Mandarin, Spanish Translation Available)

    • 06:30 - 08:00
    • 9/09/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Plenary
    • Track: N.A.
    • +

      PL02.01 - Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study

      06:30 - 06:40  |  Presenter: Melissa L Johnson

      • Abstract

      Loading...

    • +

      PL02.02 - Discussant

      06:40 - 06:47  |  Presenter: Julie Brahmer

      • Abstract

      No abstract available for this presentation

    • +

      PL02.03 - Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial

      06:47 - 06:57  |  Presenter: Luis Paz-Ares

      • Abstract

      Loading...

    • +

      PL02.04 - Discussant

      06:57 - 07:04  |  Presenter: Charles M Rudin

      • Abstract

      No abstract available for this presentation

    • +

      PL02.05 - IMpower010: Characterization of Stage IB-IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab

      07:04 - 07:14  |  Presenter: Nasser Altorki

      • Abstract

      Loading...

    • +

      PL02.06 - Discussant

      07:14 - 07:21  |  Presenter: Ichiro Yoshino

      • Abstract

      No abstract available for this presentation

    • +

      PL02.07 - Global Variability in Lung Cancer Deaths Attributable to Air Pollution

      07:21 - 07:31  |  Presenter: Christine Dorothy Berg

      • Abstract

      Loading...

    • +

      PL02.08 - Discussant

      07:31 - 07:38  |  Presenter: Joachim G.J.V. Aerts

      • Abstract

      No abstract available for this presentation

    • +

      PL02.09 - International Association for the Study of Lung Cancer (IASLC) Study of the Impacts of COVID-19 on International Lung Cancer Clinical Trials

      07:38 - 07:48  |  Presenter: Matthew Smeltzer

      • Abstract

      Loading...

    • +

      PL02.10 - Discussant

      07:48 - 07:55  |  Presenter: Marina Chiara Garassino

      • Abstract

      No abstract available for this presentation

    • +

      PL02.11 - Live Discussion with Speakers

      07:55 - 08:00

      • Abstract

      No abstract available for this presentation

  • +

    PL02A - Plenary 2: Presidential Symposium (Rebroadcast) (Japanese, Mandarin, Spanish Translation Available)

    • 14:30 - 16:00
    • 9/09/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Plenary
    • Track: N.A.
    • +

      PL02A.01 - Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study

      14:30 - 14:40  |  Presenter: Melissa L Johnson

      • Abstract

      Loading...

    • +

      PL02A.02 - Discussant

      14:40 - 14:47  |  Presenter: Julie Brahmer

      • Abstract

      No abstract available for this presentation

    • +

      PL02A.03 - Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial

      14:47 - 14:57  |  Presenter: Luis Paz-Ares

      • Abstract

      Loading...

    • +

      PL02A.04 - Discussant

      14:57 - 15:04  |  Presenter: Charles M Rudin

      • Abstract

      No abstract available for this presentation

    • +

      PL02A.05 - IMpower010: Characterization of Stage IB-IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab

      15:04 - 15:14  |  Presenter: Nasser Altorki

      • Abstract

      Loading...

    • +

      PL02A.06 - Discussant

      15:14 - 15:21  |  Presenter: Ichiro Yoshino

      • Abstract

      No abstract available for this presentation

    • +

      PL02A.07 - Global Variability in Lung Cancer Deaths Attributable to Air Pollution

      15:21 - 15:31  |  Presenter: Christine Dorothy Berg

      • Abstract

      Loading...

    • +

      PL02A.08 - Discussant

      15:31 - 15:38  |  Presenter: Joachim G.J.V. Aerts

      • Abstract

      No abstract available for this presentation

    • +

      PL02A.09 - International Association for the Study of Lung Cancer (IASLC) Study of the Impacts of COVID-19 on International Lung Cancer Clinical Trials

      15:38 - 15:48  |  Presenter: Matthew Smeltzer

      • Abstract

      Loading...

    • +

      PL02A.10 - Discussant

      15:48 - 15:55  |  Presenter: Marina Chiara Garassino

      • Abstract

      No abstract available for this presentation

    • +

      PL02A.11 - Live Discussion with Speakers

      15:55 - 16:00

      • Abstract

      No abstract available for this presentation